Pfizer Corporation

William H Martin

Dennis J Hoover

Judith L Treadway

Bernard Hulin

Douglas Phillips

Banavara L Mylari

W Ross Tracey

This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein Ris carboxy, (C-C)alkoxycarbonyl, C(O)NRRor C(O)R, useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.

Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors

Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors

This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein R is carboxy, (C -C )alkoxycarbonyl, C(O)NR R or C(O)R , useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.

Substituted N-( indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Substituted n-(indole-2-carbonyl)glycinamides and derivates as glycogen phosphorylase inhibitors

Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as

A method of preventing non-cardiac tissue damage resulting from ischemia and/or hypoxia, comprising administering to a patient in need of such treatment an effective amount of an glycogen phosphorylase inhibitor.

Method of reducing tissue damage associated with non-cardiac ischemia

Growing community of inventors

Essex, CT, United States of America

William H Martin